Compositions and methods for the early diagnosis of ovarian cancer
CA 2402017 C · Owner: The Board Of Trustees Of The University Of Arkansas · Inventors: O'Brien, Timothy J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The disclosed nucleic acid primer sets used in combination with quantitative amplification (PCR) of tissue (cDNA), can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers and their presence may serve , for early detection of associated ovarian and other malignancies and for the , design of interactive therapies for cancer treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 7, 2001 and granted July 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.